Shenzhen Kangtai Biological Products

Shenzhen Kangtai Biological Products Co., Ltd., also known as BioKangtai, is a Chinese biopharmaceutical company whose activities center on vaccine research, development, manufacturing, and commercialization. The company is listed on the Shenzhen Stock Exchange under ticker 300601.SZ. Its portfolio and manufacturing activities are associated with human vaccines, including hepatitis B and pneumonia-related products identified in reference material. Kangtai also became involved in COVID-19 vaccine development during the pandemic through its Minhai COVID-19 vaccine program. In addition, the company held the exclusive right to manufacture the Oxford–AstraZeneca COVID-19 vaccine in mainland China, according to the company’s English Wikipedia entry. This arrangement placed Kangtai within the international COVID-19 vaccine supply and technology-transfer landscape, alongside its domestic vaccine business. Publicly available reference material supplied for this dossier does not establish the company’s founding year, founder, current executives, corporate ownership structure, official website, detailed revenue profile, or the precise commercial status of each vaccine program. The available information supports describing Kangtai primarily as a China-focused vaccine manufacturer and biopharmaceutical enterprise rather than assigning it a broader pharmaceutical-conglomerate profile.

Shenzhen Kangtai Biological Products is a Chinese biopharmaceutical enterprise built around the development and manufacture of human vaccines. The company is also known as BioKangtai and is listed on the Shenzhen Stock Exchange under the code 300601. Reference material identifies its core activities as vaccine research, production, and marketing, with hepatitis B and pneumonia vaccines among its principal products. The available material does not provide a verified founding date, founder, or detailed account of the company’s early corporate development, so those details are not supplied here. Kangtai’s business profile is best understood through its role in China’s vaccine industry: it combines research and development with industrial production and distribution of products intended for human immunization. Its portfolio includes established vaccine categories as well as pandemic-response programs. During the COVID-19 pandemic, Kangtai developed the Minhai COVID-19 vaccine. The company was also associated with the Oxford–AstraZeneca vaccine through an exclusive right to manufacture that product in mainland China. This relationship connected Kangtai’s domestic manufacturing capabilities with an internationally developed vaccine platform. The supplied references do not establish whether every cited product reached routine commercial distribution, nor do they provide reliable details on regulatory approvals, production volumes, sales, financial performance, international subsidiaries, or current management. Accordingly, the company’s documented public profile in this dossier remains focused on its identity as a listed Chinese vaccine developer and manufacturer, its established human-vaccine orientation, and its COVID-19-era development and manufacturing roles.

• Listed on the Shenzhen Stock Exchange

  [1]Shenzhen Kangtai Biological Productsen.wikipedia.org

  Shenzhen Kangtai Biological Products is listed on the Shenzhen Stock Exchange under ticker 300601.SZ. The available reference does not specify the listing date.

• Development of the Minhai COVID-19 vaccine

  [1]Shenzhen Kangtai Biological Productsen.wikipedia.org

  Kangtai developed the Minhai COVID-19 vaccine during the pandemic period. The supplied reference does not provide a specific development or launch year.

• Exclusive mainland China manufacturing rights for the Oxford–AstraZeneca vaccine

  [1]Shenzhen Kangtai Biological Productsen.wikipedia.org

  The company held the exclusive right to manufacture the Oxford–AstraZeneca COVID-19 vaccine in mainland China. The reference does not specify the date on which this arrangement began.

A China-focused biopharmaceutical company specializing in human vaccine research, production, and commercialization.

• Human vaccine

  Hepatitis B vaccine

  Hepatitis B vaccine is identified among Kangtai’s main vaccine products. It represents the company’s established human-vaccine manufacturing business and its focus on products used to prevent infectious disease. The available reference does not specify the formulation, dosage presentation, target age groups, regulatory markets, or current commercial status.

• Human vaccine

  Pneumonia vaccine

  Pneumonia vaccine products are included in the company’s reported product scope. The supplied material does not identify a specific product name, pathogen target, formulation, approval history, or commercialization date, so this entry is limited to the product category described in the reference.

• COVID-19 vaccine

  Minhai COVID-19 vaccine

  The Minhai COVID-19 vaccine is a pandemic-era vaccine program developed by Kangtai. The reference confirms the development role but does not provide sufficient information about the platform, clinical results, regulatory authorization, manufacturing scale, or final market status.

• COVID-19 vaccine

  Oxford–AstraZeneca COVID-19 vaccine manufactured in mainland China

  Kangtai held the exclusive right to manufacture the Oxford–AstraZeneca COVID-19 vaccine in mainland China. This was a manufacturing and technology-related role connected with an internationally developed vaccine. The supplied reference does not state the production start date, volumes, authorization details, or duration of the exclusivity.

• 2013

  Infant deaths after vaccination led to suspension; investigation found no causal link to vaccine quality

  In late 2013, reports from several regions described infant deaths following administration of Kangtai's hepatitis B vaccine, and use of the product was temporarily suspended. In 2014, official investigations and testing indicated that the deaths were not attributable to vaccine quality, and production resumed. This entry preserves both the safety concern and the clarification: a death after vaccination does not mean the vaccine caused it.

  Source

Read more

• 2020.08.11

  Reported2020.08.11

  AstraZeneca signs vaccine licensing deal with BioKangtai[4]阿斯利康与康泰生物签署疫苗许可协议hospimedica.com

  AstraZeneca signed a licensing deal with BioKangtai to supply its AZD1222 COVID-19 vaccine candidate to China. The companies also said they would explore the possibility of producing the vaccine for other markets.

Read more

1. 1Shenzhen Kangtai Biological Productsen.wikipedia.org
2. 2Infant deaths after vaccination led to suspension; investigation found no causal link to vaccine qualitychinanews.com
3. 3Infant deaths after vaccination led to suspension; investigation found no causal link to vaccine qualitynews.sciencenet.cn
4. 4阿斯利康与康泰生物签署疫苗许可协议hospimedica.com